Opthea Raises A$171.5M in Placement and Entitlement Offer

Ticker: OPTEY · Form: 6-K · Filed: Jun 14, 2024 · CIK: 1815620

Sentiment: bullish

Topics: capital-raise, financing, clinical-development

TL;DR

Opthea just snagged A$171.5M to fund its drug development. Big win for their pipeline.

AI Summary

Opthea Limited announced on June 14, 2024, that it has successfully completed a placement and the institutional component of its entitlement offer, raising A$171.5 million (approximately US$113.2 million). This capital raise is intended to support the company's ongoing clinical development programs.

Why It Matters

This significant capital injection provides Opthea with the necessary funds to advance its promising therapies, potentially impacting the treatment landscape for certain eye diseases.

Risk Assessment

Risk Level: medium — While the capital raise is positive, the company is still in the clinical development phase, which inherently carries significant risks.

Key Numbers

Key Players & Entities

FAQ

What was the total amount raised by Opthea Limited in its recent capital raise?

Opthea Limited raised A$171.5 million (approximately US$113.2 million).

What type of capital raise did Opthea Limited complete?

Opthea Limited completed a placement and the institutional component of an entitlement offer.

When was the announcement of Opthea Limited's successful capital raise made?

The announcement was made on June 14, 2024.

What is the primary purpose of the funds raised by Opthea Limited?

The funds are intended to support the company's ongoing clinical development programs.

What is Opthea Limited's principal executive office address?

Opthea Limited's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.

Filing Stats: 156 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-06-13 19:12:07

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 06/14/2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing